Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock?Zacks Investment Research • 12/02/25
Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out?Zacks Investment Research • 11/20/25
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving AverageZacks Investment Research • 11/17/25
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5GlobeNewsWire • 11/17/25
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic DermatitisGlobeNewsWire • 11/13/25
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 26.53%: Here's is How to TradeZacks Investment Research • 11/05/25
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical DermatologyGlobeNewsWire • 11/04/25
Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 10/31/25
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term TreatmentsGlobeNewsWire • 10/30/25
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5GlobeNewsWire • 10/30/25
Arcutis' Q3 Earnings: Increased Foam Share, Better GTN, And Clear 2026 Guide Made Share RallySeeking Alpha • 10/29/25
Arcutis Biotherapeutics: Soaring On Q3 Earnings - Further Upside Likely (Upgrade)Seeking Alpha • 10/28/25
Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise.Investors Business Daily • 10/28/25
Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research • 10/28/25
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial ResultsGlobeNewsWire • 10/28/25
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology ConferenceGlobeNewsWire • 10/24/25
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 10/21/25
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5GlobeNewsWire • 10/06/25